(Reuters) -Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added subscribers and expanded its personalized healthcare offerings. The company and rivals have launched programs that offer "personalized" versions of semaglutide, the active ingredient in weight-loss drug Wegovy, at doses not accessible through the branded manufacturers, following the government's ban on the mass production of copies of those drugs. Hims and Hers' subscriber base ...